Last reviewed · How we verify
NNC 0142-0000-0002 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
NNC 0142-0000-0002 (NNC 0142-0000-0002) — Janssen Research & Development, LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NNC 0142-0000-0002 TARGET | NNC 0142-0000-0002 | Janssen Research & Development, LLC | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NNC 0142-0000-0002 CI watch — RSS
- NNC 0142-0000-0002 CI watch — Atom
- NNC 0142-0000-0002 CI watch — JSON
- NNC 0142-0000-0002 alone — RSS
Cite this brief
Drug Landscape (2026). NNC 0142-0000-0002 — Competitive Intelligence Brief. https://druglandscape.com/ci/nnc-0142-0000-0002. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab